Amylin Commands Weight-Loss Attention as Industry Anticipates Novo’s Phase III CagriSema Readout

Amylin analogs present a strong alternative or complement to GLP-1 receptor agonists, potentially eliciting higher-quality weight-loss with a cleaner tolerability profile.